TEVA.TA - Teva Pharmaceutical Industries Limited

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
5,115.00
-37.00 (-0.72%)
As of 2:50PM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close5,152.00
Open5,150.00
Bid5,114.00 x 200
Ask5,119.00 x 34100
Day's Range5,110.00 - 5,175.00
52 Week Range51.41 - 5,175.00
Volume449,231
Avg. Volume1,174,012
Market Cap51.97B
Beta-0.58
PE Ratio (TTM)-837.43
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (7.11%)
Ex-Dividend Date2017-03-02
1y Target EstN/A
  • 3 Value Stocks for Retirees
    Motley Fool20 minutes ago

    3 Value Stocks for Retirees

    With retirees living longer than ever, these value stocks offer an opportunity to really grow your nest egg.

  • MarketWatch20 hours ago

    Shares of large generic drugmakers fall

    Shares of several large generic drugmakers fell in Wednesday midday trade. Mylan NV shares dropped 2.7%, Teva Pharmaceutical Industries Ltd. shares dropped 2.1% , Taro Pharmaceutical Industries Ltd. shares ...

  • Reuters2 days ago

    Amneal, Impax combine to tackle generic drug pricing pressure

    The deal comes at a time when speedy approvals of generics by U.S. regulators have ratcheted up competition in the sector, mounting pressure on smaller drugmakers such as Impax, which has a market cap of about $1.48 billion (£1.1 billion). Adding to the woes of generics makers, U.S. retail pharmacies including Wal-Mart Stores Inc (WMT.N) and Walgreens Boots Alliance Inc (WBA.O) are wielding more leverage when buying such drugs, leading to continued price erosion.

  • Reuters2 days ago

    Incoming Teva Pharm CEO Schultz to start by month end -newspaper

    Kare Schultz will start his new post as chief executive of Israel's Teva Pharmaceutical Industries by the end of October, the Calcalist financial newspaper reported on Tuesday. A Teva spokesman, asked about the Israeli news report, said the company does not comment on market rumours. Teva poached Schultz from Denmark's Lundbeck in September, handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future.

  • SmarterAnalyst2 days ago

    Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Submits Biologics License Application to the FDA for Migraine Treatment

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. TEVA Chief Scientific Officer Michael Hayden commented, "The BLA submission for fremanezumab marks a very important milestone for the migraine community [...] There have been few therapeutic innovations for migraine patients in over 25 years. If approved, fremanezumab will be among the first to enter the market in a new class of drugs for the preventive treatment of migraine.

  • Allergan Tanks After Judge Invalidates Restasis Patents
    Investor's Business Daily3 days ago

    Allergan Tanks After Judge Invalidates Restasis Patents

    Allergan tanked Monday after a federal judge invalidated patents covering eye-drug Restasis.

  • 24/7 Wall St.6 days ago

    PG&E, Teva Pharmaceuticals Dive into Friday’s 52-Week Low Club

    PG&E, Teva Pharmaceuticals, Vipshop, and 3D Systems all posted new 52-week lows Friday.

  • Motley Fool6 days ago

    A New FDA Approval Sends Small Cap Flexion Soaring

    Flexion's non-opioid pain management drug has huge potential, and it's looking to expand into more indications.

  • Motley Fool6 days ago

    Why Do Companies Pay Dividends?

    There are some good reasons to pay dividends, but it’s not the right move for all companies.

  • American City Business Journals7 days ago

    BDSI settles patent litigation with generic giant Teva

    BDSI further said that additional terms of the settlement agreement are confidential and that the agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. A Teva spokeswoman confirmed the settlement agreement and launch date.

  • Capital Cube7 days ago

    Teva Pharmaceutical Industries Ltd. – Value Analysis (TEL AVIV:TEVA) : October 12, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Teva Pharmaceutical Industries Ltd. a score of 75. Our analysis is based on comparing Teva Pharmaceutical Industries Ltd. with the following peers – Compugen Ltd. and XTL Biopharmaceuticals Ltd. (CGEN-IL and XTLB-IL). Investment Outlook Teva Pharmaceutical Industries Ltd. has a fundamental score of 75 and has a ... Read more (Read more...)

  • Mylan Deals a Blow to Teva Pharmaceutical
    Motley Fool8 days ago

    Mylan Deals a Blow to Teva Pharmaceutical

    Mylan's latest drug approval could take a big chunk out of Teva Pharmaceutical's revenue.

  • Teva Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TEVA-IL : October 11, 2017
    Capital Cube8 days ago

    Teva Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TEVA-IL : October 11, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Teva Pharmaceutical Industries Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • The Wall Street Journal9 days ago

    [$$] CVC Picks Former Allergan Executive to Run Women's Drug Portfolio

    Anish Mehta oversaw the $40.5 billion sale of Allergan’s generics business in 2016.

  • Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
    Zacks10 days ago

    Forget Teva (TEVA), Buy These 5 Drug Stocks Instead

    With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.

  • GuruFocus.com11 days ago

    Stocks That Fell to 3-Year Lows in the Week of Oct. 6

    BT Group PLC (BT), Cardinal Health Inc. (CAH), Teva Pharmaceutical Industries Ltd (TEVA), and Chipotle Mexican Grill Inc. (CMG) have declined to their respective three-year lows.

  • TheStreet.com13 days ago

    Not His Cup of Teva; Recommended Reading: Best of Kass

    In highlights from this week's trading diary and posts, Kass discusses Teva and offers some recommended reading.

  • Is Allergan plc a Bargain After a $7.6 Billion Dip in September?
    Motley Fool13 days ago

    Is Allergan plc a Bargain After a $7.6 Billion Dip in September?

    Allergan continues to be a victim of Teva's downfall.

  • Reuters14 days ago

    Teva's Copaxone faces generic competition in Europe after U.S. hit

    Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market. Mylan's European partner, Synthon, and Alvogen said on Thursday they had received decentralized European approval for a 40 milligram dose of glatiramer acetate, as Copaxone is known generically. Nearly 20 percent of total sales for Teva Pharmaceutical Industries comes from branded Copaxone.

  • Reuters14 days ago

    Teva's Copaxone faces more generic competition in Europe

    Teva's blockbuster multiple sclerosis treatment Copaxone faces more generic competition in Europe, just two days after regulators approved cut-price copies of the medicine in the United States. Privately held Alvogen and Synthon said on Thursday they had received decentralised European approval for a 40 mg dose of glatiramer acetate, as Copaxone is known generically. Copaxone is Teva's best-selling drug, generating more than $4 billion in revenue for the Israeli drugmaker last year.

  • TheStreet.com14 days ago

    Teva Investors Concerned Debt Could Be Cut to Junk Rating

    Teva's enormous debt load is getting heavier by the second, Evercore ISI says.

  • Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early
    Zacks14 days ago

    Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early

    Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.

  • MarketWatch14 days ago

    Mylan’s surprise generic win sends Teva, Momenta shares plunging

    The multiple sclerosis drug Copaxone brought in $4 billion last year for Teva, and generic competition wasn’t expected until at least 2018.

  • The Wall Street Journal14 days ago

    [$$] Even Tougher Choices Ahead for Teva After FDA Shocker

    A surprise move from the Food and Drug Administration means that a recovery for Teva Pharmaceutical Industries just got much more difficult.

  • TheStreet.com15 days ago

    Shopify Drops After Citron Note; Verizon Is Protected From Yahoo Drama -- ICYMI

    Here's what you need to know now for Wednesday, Oct. 4.